Current position

Cathie Wood’s Adaptive Biotechnologies Corp (ADPT) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

ARK Investment ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2020Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares12.81MHighest verified quarter-end share count
Quarters reported25Verified quarters with shares above zero
What happened?

ARK Investment Management first reported Adaptive Biotechnologies Corp in Q2 2020. The reported position was increased and reduced across later filings. ARK Investment Management currently reports 2.09M shares. The latest verified filing showed: Sold 0.1% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 0.1% of the position−2.66K shares · 2.09M shares remained
Filing context

Quarter-end price $21.45 · Estimated holding basis $21.19

Q1 2026
Sold 2.2% of the position−45.99K shares · 2.09M shares remained
Filing context

Quarter-end price $13.88 · Estimated holding basis $21.19

Q4 2025
Sold 32.4% of the position−1.03M shares · 2.14M shares remained
Filing context

Quarter-end price $16.24 · Estimated holding basis $21.19

Q3 2025
Sold 21.2% of the position−850.85K shares · 3.17M shares remained
Filing context

Quarter-end price $14.96 · Estimated holding basis $21.19

Q2 2025
Sold 48.1% of the position−3.72M shares · 4.02M shares remained
Filing context

Quarter-end price $11.65 · Estimated holding basis $21.19

Q1 2025
Sold 17.9% of the position−1.69M shares · 7.73M shares remained
Filing context

Quarter-end price $7.43 · Estimated holding basis $21.19

Portfolio importance

How important is Adaptive Biotechnologies Corp in ARK Investment Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.3%Q2 2026
Current rank#64of 190 reported positions
Peak portfolio weight0.6%Q4 2022
Best historical rank#32Q1 2023
At peak importanceQ4 2022
ADPT
0.6%
Largest holding
6.9%
Cross-investor discovery

Who else owns Adaptive Biotechnologies Corp?

Also reported by 2 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
ADPT0.0% of reported portfolio
Ray DalioBridgewater Associates, LP
ADPT0.0% of reported portfolio
Explore Adaptive Biotechnologies Corp across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$27.672026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$21.45Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$21.19Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows ARK Investment Management’s aggregated Form 13F disclosures. It is not Cathie Wood’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.